Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney filter study tests safer dialysis for acute kidney failure

NCT ID NCT07679568

Knowledge-focused Sponsor: Fresenius Medical Care Deutschland GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study looks at how well a specific kidney filter (multiFlux 160) works when used with two different blood thinners—heparin or citrate—during continuous kidney replacement therapy. The goal is to see which approach keeps the filter working effectively while avoiding side effects like electrolyte imbalances. The study includes adults and children with acute kidney injury who need this therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
multiFlux 160 hemofilter
What this could lead to
If successful, this study could help doctors choose the best blood thinner for kidney dialysis in critically ill patients, potentially improving treatment safety and effectiveness.
What could go wrong
This is a small observational study, not a large trial. It cannot prove which approach is better overall, and results may not apply to all patients with kidney injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 62 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of critically ill patients (adults and children) requiring continuous kidney replacement therapy (CKRT).

Ages

1 year and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: General: Patients ≥ 18 years: * Informed consent signed and dated by the investigator; and 1. if patient is able to give consent: by the study patient 2. if patients unable to give consent: by the legal representative/spouse according to § 1358 BGB or 3. if an emergency situation is determined: by an independent consultant physician. Pediatric Patients \< 18 years: * Informed consent signed and dated by legal representative and investigator/ authorized physician. * The minors have received the information referred to in Article 63(2) Medical Device Regulation (MDR) in a way adapted to their age and mental maturity and from investigators or members of the investigating team who are trained or experienced in working with children. If able, the minors have to sign the informed consent, too. * The explicit wish of a minor who is capable of forming an opinion and assessing the information referred to in Article 63(2) MDR to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator Study specific: * Body weight ≥ 8kg * Acute Kidney Injury (AKI) with clinical indication for CKRT * Clinically estimated life expectancy greater than 3 days Exclusion Criteria: * Any conditions which could interfere with the patient's ability to comply with the study * Patient or legal representative or authorized physician during emergency situation is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations * Participation in a different interventional clinical study during the preceding 30 days * Previous participation in the same study * Uncontrolled bleeding and coagulation disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Renal failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Klinikum der Ludwig-Maximilians-Universität München (LMU Klinikum)

    Munich, Bavaria, 81377, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.